Evidence map›Paper›PMID 33096812›Full record

ReviewInternational journal of molecular sciences2020

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020.

Peter Everts, Kentaro Onishi, Prathap Jayaram, José Fábio Lana, Kenneth Mautner

5 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 510 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
510citing papers in PubMed, 19 pooled it
88.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04797377 nacompletednot on this mapstarted 2021, after this paper: background citation

Effects of Autologous Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response

TypeinterventionalSponsorNadezhda Women's Health HospitalRan2021 to 2021Enrolled66ConditionsPoor Ovarian ReserveArmsAutologous ovarian PRP injection
NCT06453603 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome, Randomized Controlled Trial Study

TypeinterventionalSponsorRamathibodi HospitalRan2024 to 2026Enrolled24ConditionsPes Anserine Bursitis, Steroid Injection, PRP InjectionArmsPRP injection, corticosteroid injection
NCT06472323 recruitingnot on this mapstarted 2024, after this paper: background citation

The Efficacy and Safety of Pulsed Radiofrequency(PRF) Combined With Platelet-rich Plasma Versus PRF Alone for the Trigeminal Neuralgia

TypeobservationalSponsorBeijing Tiantan HospitalRan2024 to 2026Enrolled270ConditionsTrigeminal Neuralgia, Idiopathic, PRPArmsPRF+PRP, PRF
NCT06998433 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia: A Randomized Clinical Trial

TypeinterventionalSponsorBaylor College of MedicineRan2025 to 2026Enrolled56ConditionsCentral Centrifugal Cicatricial AlopeciaArmsPlatelet-Rich Plasma (PRP) Injections, Saline
NCT07688096 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Regenerative Medicine for Joint Hypermobility and Instability: A Prospective, Open-Label, Single-Arm, Step-Care Clinical Study

TypeinterventionalSponsorManhattan Pain Medicine, PLLCRan2026 to 2028Enrolled100ConditionsEhlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS), Joint Hypermobility, Joint InstabilityArmsDextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational), Visco-3 Sodium Hyaluronate Viscosupplementation
3 · Its place in the literature

Who cites it

510 citing papers in PubMed, 19 syntheses or guidelines pooled it, 911 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

450 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Peter EvertsGulf Coast Biologics, Research and Science Division, Fort Myers, FL 33916, USA.ORCID 0000-0003-3128-9380
Kentaro OnishiDepartment of PM&R and Orthopedic Surgery, University of Pittsburg Medical Center, Pittsburgh, PA 15213, USA.
Prathap JayaramDepartment of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX 77030, USA.
José Fábio LanaThe Bone and Cartilage Institute, Indaiatuba, Sao Paulo, Brazil.
Kenneth MautnerEmory Sports Medicine and Primary Care Sports Medicine, Emory University, Atlanta, GA 30329, USA.
Baylor College of Medicine · USEmory University · USFlorida Gulf Coast University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging autologous cellular therapies that utilize platelet-rich plasma (PRP) applications have the potential to play adjunctive roles in a variety of regenerative medicine treatment plans. There is a global unmet need for tissue repair strategies to treat musculoskeletal (MSK) and spinal disorders, osteoarthritis (OA), and patients with chronic complex and recalcitrant wounds. PRP therapy is based on the fact that platelet growth factors (PGFs) support the three phases of wound healing and repair cascade (inflammation, proliferation, remodeling). Many different PRP formulations have been evaluated, originating from human, in vitro, and animal studies. However, recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, progress has been made in understanding PRP technology and the concepts for bioformulation, and new research directives and new indications have been suggested. In this review, we will discuss recent developments regarding PRP preparation and composition regarding platelet dosing, leukocyte activities concerning innate and adaptive immunomodulation, serotonin (5-HT) effects, and pain killing. Furthermore, we discuss PRP mechanisms related to inflammation and angiogenesis in tissue repair and regenerative processes. Lastly, we will review the effect of certain drugs on PRP activity, and the combination of PRP and rehabilitation protocols.

Indexed as

Platelet-Rich PlasmaAdaptive ImmunityAgingAnalgesicsAngiogenesis Inducing AgentsAnti-Inflammatory Agents, Non-SteroidalCellular SenescenceHumansImmunity, InnateIn Vitro TechniquesOsteoarthritisPlatelet TransfusionRehabilitationSerotoninTerminology as TopicAnalgesicsAngiogenesis Inducing AgentsAnti-Inflammatory Agents, Non-SteroidalSerotoninanalgesic effectsangiogenesisimmunomodulationinflammationlymphocytesmonocytesneutrophilsplatelet dosingplatelet-rich plasmaregenerative medicinerehabilitationserotonin

Identifiers

PMID33096812
PMCPMC7589810
OpenAlexW3091097189

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.